Primary Health Care, South Rwenzori Diocese, Kasese, Uganda.
J Altern Complement Med. 2009 Nov;15(11):1231-7. doi: 10.1089/acm.2009.0098.
The leaves of the shrub Vernonia amygdalina Del (Compositae) are widely used in Africa to treat malaria. It is widely available, accessible, and affordable in many remote areas that do not have ready access to modern medicines.
This study examined the efficacy and safety of an infusion of fresh V. amygdalina leaves for the treatment of uncomplicated malaria in patients aged 12 years and over.
The primary outcome measure was an adequate clinical response. The secondary outcome measure was incidence of adverse events, assumed to be side-effects of the medicine.
The remedy was associated with an adequate clinical response (ACR) at day 14 in 67% of cases. However, complete parasite clearance occurred in only 32% of those with ACR, and of these, recrudescence occurred in 71%. There was no evidence of significant side-effects or toxicity from the medication. There was a trend toward a reduction in hemoglobin between day 0 and day 28, although this did not reach statistical significance.
Further studies are needed to determine whether the efficacy can be improved by increasing the dose, changing the preparation, or adding other antimalarial plants.
灌木黄麻 Vernonia amygdalina Del(菊科)的叶子在非洲被广泛用于治疗疟疾。在许多无法获得现代药物的偏远地区,它广泛存在、易于获得且价格低廉。
本研究评估了新鲜黄麻叶浸剂治疗 12 岁及以上患有单纯性疟疾患者的疗效和安全性。
主要结局指标是充分的临床反应。次要结局指标是不良事件的发生率,假定为药物的副作用。
在第 14 天,该疗法与 67%的病例中的充分临床反应(ACR)相关。然而,在那些具有 ACR 的患者中,仅有 32%的患者完全清除寄生虫,而在这些患者中,有 71%的患者出现复发。该药物没有明显的副作用或毒性证据。尽管没有达到统计学意义,但血红蛋白在第 0 天和第 28 天之间有下降的趋势。
需要进一步研究以确定通过增加剂量、改变制剂或添加其他抗疟植物是否可以提高疗效。